Killing two birds with one stone: a case of GIST and supervening CML.

about

Killing two birds with one stone: a case of GIST and supervening CML.

Item

http://www.wikidata.org/entity/Q43211315

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Killing two birds with one stone: a case of GIST and supervening CML.

@en

Killing two birds with one stone: a case of GIST and supervening CML.

@nl

type

Item

label

Killing two birds with one stone: a case of GIST and supervening CML.

@en

Killing two birds with one stone: a case of GIST and supervening CML.

@nl

prefLabel

Killing two birds with one stone: a case of GIST and supervening CML.

@en

Killing two birds with one stone: a case of GIST and supervening CML.

@nl

P1476

Killing two birds with one stone: a case of GIST and supervening CML.

@en

P2093

Michael Rachshtut

http://www.w3.org/2001/XMLSchema#string

Uyen Hoang

http://www.w3.org/2001/XMLSchema#string

Uzma Khan

http://www.w3.org/2001/XMLSchema#string

Vivek Rashmikant Mehta

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.

Targeted therapy in GIST: in silico modeling for prediction of resistance.

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.

A newborn with teratogenic effect of imatinib mesylate: a very rare case report

Synchronous gastrointestinal stromal tumors (GIST) and other primary cancers: case series of a single institution experience.

P31

scholarly article

P356

10.1136/BCR-2015-211698

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26468222

http://www.w3.org/2001/XMLSchema#string

P932

4612301

http://www.w3.org/2001/XMLSchema#string